You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

Biogen Idec sets price for new MS pill

Biogen Idec Inc. said Friday it will price Tecfidera, its newly approved pill to treat multiple sclerosis, at $54,900 a year per patient in the United States.

Officials at the Weston-based biotechnology company said the figure represents a “solid value” for MS patients, who will take the capsule twice a day. Most MS treatments now on the market have to be injected or taken through intravenous infusion.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week